双成药业(002693) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥73,230,987.79, a decrease of 12.57% compared to ¥83,759,538.77 in the same period last year[3]. - Net profit attributable to shareholders was ¥730,119.24, representing a significant increase of 121.62% from a net loss of ¥3,377,608.14 in the previous year[3]. - Basic earnings per share improved to ¥0.0018, up 118.00% from a loss of ¥0.01 per share in the same period last year[3]. - The company's net loss for the first quarter of 2022 was RMB 2,489,615.08, an improvement from a loss of RMB 8,153,305.80 in the previous year[27]. - The total comprehensive income for the first quarter was -2,497,156.47 CNY, improved from -8,165,356.09 CNY year-over-year[28]. Assets and Liabilities - Total assets increased by 3.37% to ¥883,386,626.72 from ¥854,556,164.94 at the end of the previous year[3]. - The total liabilities rose to RMB 317,411,619.14, up from RMB 287,804,887.63, indicating an increase of 10.4%[26]. - The company's inventory increased to RMB 57,577,217.54 from RMB 55,241,621.73, showing a growth of 4.2%[25]. Cash Flow - The net cash flow from operating activities decreased by 283.07% to -¥15,284,942.57, primarily due to reduced sales returns from price drops under national procurement policies[3][10]. - Cash inflow from operating activities totaled 80,330,695.21 CNY, down from 88,072,723.46 CNY year-over-year, reflecting a decrease of approximately 8.5%[31]. - Cash outflow from operating activities was 95,615,637.78 CNY, compared to 92,062,840.28 CNY in the same period last year, indicating an increase of about 3.0%[31]. - Cash flow from investing activities resulted in a net outflow of -41,225,949.49 CNY, a decline from a net inflow of 61,817,927.71 CNY in the previous year[31]. - Cash flow from financing activities generated a net inflow of 49,291,851.39 CNY, compared to a net outflow of -49,847,933.61 CNY in the same period last year, showing a significant improvement[32]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,017[13]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 33.86% of shares, totaling 139,516,546 shares[13]. - HSP Investment Holdings Limited, the second-largest shareholder, holds 15.76% of shares, totaling 64,915,479 shares[13]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for over 50% of total shares[13]. Stock Options and Incentives - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at a price of 1.91 RMB per share[15]. - The stock option plan includes 700,000 options granted at a price of 3.82 RMB per option, with 81 participants[15]. - As of April 2022, the company adjusted the stock option plan, reducing the number of options from 692.20 million to 684.25 million due to the departure of three participants[19]. - The first exercise period for the stock options is set from May 6, 2022, to May 5, 2023[20]. - The company has completed the registration of stock options and restricted stock grants, with a total of 75 participants in the stock option plan[18]. Other Income and Expenses - Research and development expenses decreased by 42.33% compared to the previous year, as some projects reached capitalization conditions[8]. - Other income increased by 546.27% year-on-year, mainly due to rewards received for the consistency evaluation of generic drug quality and efficacy[8]. - The company reported a 95.39% decrease in investment income, attributed to reduced financial management returns during the reporting period[8]. - Cash and cash equivalents decreased by 190.72% year-on-year, influenced by reduced sales returns and decreased financial management cash flow[10].